

GRANTS AND BURSARIES							
APRIL 1, 2010 - MARCH 31, 2011							
NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
		JGH Totals (External grants include career awards)	27 441 690		6 389 445		8 722 785
Operating Grants & Awards		Medicine Totals (External grants include career awards, fellows)	19 990 071				
		Medicine - Totals	18 837 543	1 152 528	4 720 080	168 000	3 532 603
Alaoui Jamali	Cancer Research Society	Focal Adhesion Regulators of Early Invasive Breast Cancer: Therapeutic Targeting in Preclinical Models and Clinical Validation in Progressive Breast Cancer.	150 000				
Alaoui Jamali	Canadian Institutes for Health Research	Discovery and Validation of Pharmacological Probes for Understanding Protein-protein Interactions of Focal Adhesion Signalling in Invasive Cancer Cells.	145 084				
Alaoui Jamali	National Cancer Institute of Canada	Canadian Breast Cancer Research Initiative - Molecular and Functional Studies of Focal Adhesion Protein Trafficking And Turnover in Invasive Cancer Cells	127 500				
Alaoui Jamali	Canadian Institutes for Health Research	Investigation of the Filamin Signaling Network's Function in Cancer Progression	78 416				
Alaoui Jamali	Grouping of Canadian Individuals	Stipend for Dr. Sabrina Daniela Silva Wurzba	30 000				
Alaoui Jamali	Cancer de la prostate Canada	Targeting a Novel Heme Oxygenase Signaling Pathway in Prostate Cancer and Therapeutic Applications.	30 000				
Alaoui Jamali	National Cancer Institute of Canada	Mechanism of Gap Junction Downregulation in Mammary Tumor Cells and Potential Therapeutic Implications in Breast Cancer.	15 000				
Aloyz, R.	Canadian Institutes for Health Research	Mechanisms of Dasatinib Cytotoxicity and Sensitization to Standard Therapy in Chronic Lymphocytic Leukemia	46 097				
Aloyz, R.	The WeekEnd to Breast Cancer	Effect of XRCC3, a Dan Repair Associated Gene, on Cell Adhesion and Motility.	40 000				
Aloyz, R.	Leukemia and Lymphoma Society	Assessment of a Telomerase Inhibitor in Chronic Lymphocytic Leukemia	31 897				
Assouline, S.	Fonds de la recherche en santé du Québec	Subvention d'établissement de jeune chercheur clinicien	10 000				
Autexier, C.	Canadian Institutes for Health Research	Telomerase Structure and Function.	121 604				
Autexier, C.	Institut de recherche de la Société cana	Telomerase, Telomere Integrity and Cancer	95 289				
Autexier, C.	Canadian Institutes for Health Research	Supramolecular Complexes as G-quadruplex Binders: Towards Effective Telomerase Inhibition.	22 664				
Autexier, C.	Canadian Institutes for Health Research	Investigation of Telomere and Telomerase Regulation by Associated Proteins and in Primary Malignant Lymphocytes.		35 000			
Autexier, C.	Canadian Institutes for Health Research	Telomerase Processivity and Telomere Length Regulation.		2 500			
Baron, M.	Scleroderma Society of Canada	Canadian Scleroderma Research Group.	371 918				
Baron, M.	Canadian Institutes for Health Research	Strategic Training Initiative - Canadian Scleroderma Research Group.	300 000				
Baron, M.	Canadian Institutes for Health Research	A New Emerging Team: The Canadian Scleroderma Research Group.	179 173				
Baron, M.	Canadian Institutes for Health Research	Meeting of the Canadian Consortium of Rheumatology Cohorts (Cancer)	20 000				
Batist G.	Fonds de la recherche en santé du Québec	Programme du Fonds d'innovation Pfizer-FRSQ.	500 000				
Batist G.	Sir Mortimer B. Davis Jewish General H	Segal Research Coordination	382 365				
Batist G.	Amgen Canada Inc.	Ph+-Batist-colorectal Cancer New Treatments (Amga)	80 000				
Batist G.	Fonds de la recherche en santé du Québec	Réseau de la recherche sur le cancer du FRSQ - Axe: Thérapies expérimentales.	55 000				
Batist G.	Fonds de la recherche en santé du Québec	Réseau Provincial - Cancer.	55 000				
Batist G.	Valorisation recherche Québec Vera	Vera - Fonds de Démarrage - Re: Chi.	36 748				
Batist G.	The WeekEnd to Breast Cancer	Role of The EphB2 Receptor in Breast Cancer Metastasis	35 000				
Batist G.	Canadian Institutes for Health Research	EphB2, a Novel Target for Gamma-secretase Inhibitors (SIS) in Cancer Therapy	31 250				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Batist G.	Canadian Institutes for Health Research	2nd Quebec Conference on Therapeutic Resistance in Cancer	17 500				
Beitel, L.	Université Laval	Opto-impedimetric Screening of Blood-borne Pathogens	2 000				
Beland F	Canadian Institutes for Health Research	CIHR Team in Frailty and Aging	826 591				
Beland F	Ministère de la santé et des serv sociaux	FRELE: Fragilité, une étude longitudinale de ses expressions et accès, utilisation et coûts des services sociaux et de sante associés aux profils et trajectoires de fragilité	179 025				
Beland F	Canadian Institutes for Health Research	Qualité des soins lors des transitions des personnes âgées atteintes de maladies chroniques: une analyse des trajectoires et des pratiques de gestion cliniques		45 000			
Bergman H.	Acker Finley Inc.	Ronald Oberlander Fellow	20 000				
Bergman H.	Fondation Gustav Levinski	Oncology Research and Clinical Program for the Frail Elderly	1 500				
Bergman H.	Fondation Gustav Levinski	Canadian Initiative on Frail Older Persons	31				
Bergman H.	Fonds de la recherche en santé du Québec	Réseau québécois de recherche sur le vieillissement	(34 594)				
Blank V.	Canadian Institutes for Health Research	Role of NRF3 Transcription Factor in Lymphomagenesis	99 413				
Blank V.	National Cancer Institute of Canada	Basic Leucine Zipper Proteins as Novel Markers for Breast Cancer	69 100				
Blank V.	Natural Science & Engineering Res Council	Regulators Mediating the Proinflammatory Cytokine Response In Uterine Smooth Muscle Cells	54 488				
Blank V.	Ministère de la santé et des serv sociaux	Mission recherche	9 000				
Blank V.	Canadian Institutes for Health Research	Analysis of Novel Regulators of Erythroid Differentiation		22 000			
Blank V.	National Cancer Institute of Canada	The Role of CNC Transcription Factors in Carcinogenesis		5 625			
Blostein M.	Canadian Institutes for Health Research	Role of Gas6 in Vascular Biology	97 947				
Blostein M.	Canadian Hemophilia Society	Use of Amphipathic Helical Peptides Coupled to Nanofibrous Micrispheres to Control Hemorrhagic External Bleeding in Hemophiliacs	68 750				
Blostein M.	Canadian Institutes for Health Research	CIHR Team Grant in Venous Thromboembolism	30 000				
Blostein M.	Heart & Stroke Foundation Quebec	Physiology of Gas6-Ax1 Interaction in Endothelial Cells	29 500				
Blostein M.	Canadian Institutes for Health Research	CIHR - A Double-blind Randomized Control Trial of Post-operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism	1 989				
Cen, S.	Canadian Institutes for Health Research	The Potential of Apobec 3g in the Development of a Novel Anti-HIV-1 Therapeutic	109 331				
Chalifour L.	Canadian Institutes for Health Research	Steroid Hormone Programming in Heart	109 987				
Chalifour L.	Natural Science & Engineering Res Council	Mechanism of EGR-1 Control of Cardiac Calcium Homeostasis	22 035				
Chertkow H.	Canadian Institutes for Health Research	Cognitive Neuroscience Studies of Language in Alzheimer's Disease	149 843				
Chertkow H.	Canadian Institutes for Health Research	Establishing Prognostic Subgroups in Mild Cognitive Impairment	126 503				
Chertkow H.	Canadian Institutes for Health Research	CIHR- Dr. Kenneth Rockwood - Dalhousie University (Nova Scotia) - Create the Canadian Dementia Knowledge Translation Network (CDKTN).	21 326				
Chertkow H.	Université de Montréal	Oth-Chertkow H.-axe Cognition/rqrv/u.mtl	10 875				
Chertkow H.	Alzheimer Society of Canada	Longitudinal Study of the Neuropsychological, Neuroanatomical and Salivary Cortisol Profiles of Individuals with Mild Cognitive Impairment.		10 265			
Chong	The WeekEnd to Breast Cancer	BRCA1 and BRCA2 Mutation Screening Using High Resolution Melting Analysis - A Pilot Project	40 000				
Cohen A.	Grouping of Canadian Comp. and Corp.	N/a	70 000				
Cohen A.	CUSM Centre universit. de santé McGill	Alain Bitton - Univ. Mtl. - NIH - Ibd Genetics Consortium.	2 000				
Cohen,R.	National Cancer Institute of Canada	Palliative Care.	23 010				
Cohen,R.	Canadian Institutes for Health Research	Addressing the Needs of Culturally Diverse Family Caregivers in Palliative Care.		35 000			
Eisenberg M.	Canadian Institutes for Health Research	Unconventional Smoking Cessation Aids: a Meta-analysis of Randomized Controlled Trials	19 406				
Eisenberg M.	Heart & Stroke Foundation Quebec	The Efficacy of Weight Loss Interventions: a Systematic Review and Hierarchical Bayesian Meta-analysis.	10 000				
Eisenberg M.	Heart & Stroke Foundation Quebec	Prix John J. Day & Prix Feifer.		9 750			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Foulkes W.	Us Army Medical Research & Material Comm	Exploring the Pathogenic and therapeutic Implications of Aberrant Splicing in Breast Cancer.	132 806				
Foulkes W.	Alliance can. de la rech. sur cancer du sein	CBCRA - Fusion Transcripts: The Dark Matter of BRCA1 Tumours?	99 864				
Foulkes W.	The WeekEnd to Breast Cancer	Analysis of the BRCA1-related Breast Cancer Transcriptome at Single Nucleotide Resolution	75 000				
Foulkes W.	Susan G. Komen Breast Cancer Foundation	Susan G. Komen Breast Cancer Foundation Grant with Dr. Jun Zhu - Systematic Characterization of Dasatinib Sensitivity and Resistance in BRCA Cells.	44 815				
Foulkes W.	Fonds de la recherche en santé du Québec	Réseau de recherche sur le cancer (Axe banque de tissus et de données).	30 000				
Foulkes W.	Mendon F. Schutt Family Fund (The)	Screening Dicer-like Families for Large Deletions in Dicer1 or for Mutations or Deletions of Dicer1-like Genes	27 057				
Friedman G.	Regroupement Compagn. fond. et particul.	Gastroenterology Research	43				
Galipeau J.	National Cancer Institute of Canada	McMaster Univeristy - Jonathan Bramson - Cancer Immunotherapy Program	52 004				
Galipeau J.	Fonds de la recherche en santé du Québec	Regroupement stratégique québécois pour la recherche et Le développement de la thérapie cellulaire et génique pour les maladies hémovasculaires	50 000				
Galipeau J.	Réseau des centres d'excellence fédérale	Stem Cell-based Gene Transfer of Hemophilia a (CT3)	15 000				
Galipeau J.	Canadian Institutes for Health Research	Détermination des processus moléculaires impliqués dans l'immunomodulation par les cellules stromales mésenchymateuse issues de la moelle osseuse		35 000			
Gatignol A.	Canadian Institutes for Health Research	Exploring Interactions Between HIV and the RNA Interference Pathway	123 557				
Gatignol A.	Canadian Institutes for Health Research	CIHR-Virus-cell Interactions in the Regulation of HIV Translation	97 281				
Gatignol A.	Canadian Institutes for Health Research	Regulation of HIV-1 Replication by RNA Interference and Proteins of the Risc		50 000			
Gatignol A.	Canadian Institutes for Health Research	Developmental and Characterization of Antiretroviral RNAs to Target HIV Replication		35 000			
Greenaway C.	Fonds de la recherche en santé du Québec	Une étude de population sur l'hépatite virale chez les immigrants: fardeau, coûts et détermination de l'intervention optimale	61 149				
Hilzenrat N.	Grouping of Canadian Comp. and Corp.	Inv-Hilzenrat N.- Clinical Service	183 560				
Hilzenrat N.		Inv-Hilzenrat N - Research	6 000				
Hiscott J.	Canadian Institutes for Health Research	Regulation of Cytokine Gene Expression by the IRF Transcription Factors	179 220				
Hiscott J.	Canadian Institutes for Health Research	Regulation of Toll-like Receptor-independent and Independent Antiviral Pathways during De Novo HIV-1 Infection	159 526				
Hiscott J.	Canadian Institutes for Health Research	Oncolytic Virus Therapy for HTLV-1 Induced Adult T Cell Leukemia	74 869				
Hiscott J.	National Cancer Institute of Canada	Molecular Mechanisms Regulating T Cell Leukemogenesis By HTLV-1 Tax Protein	36 400				
Hiscott J.	Canadian Institutes for Health Research	Neuroinflammation CIHR Strategic Training Program Integrated Training Program in Basic and Clinical Aspects of Neuroinflammation		20 000			
Hiscott J.	Canadian Institutes for Health Research	Role of Toll-like Receptors (TLRs) in the Human Immunodeficiency Virus-1 (HIV-1) Replication in Human Primary Macrophages		2 500			
Hoffer J.	Lotte & John Hecht Memorial Foundation	Study - Intravenous Vitamin C in Combination with Chemotherapy in Lung Cancer Patients	100 000				
Hoffer J.	Immunotec recherche	Develop and Validate Laboratory Methods to Measure Plasma Reduced Cysteine (rCys), Total Cysteine (All Cysteine Molecules Including Protein Bound, Cystine, and Mixed Disulfides), and Asparagine	25 148				
Hoffer J.	McGill University	Implications of Hypovitaminosis C in Actutely Ill Hospitalized Patients	11 797				
Hudson M.	Canadian Institutes for Health Research	Development and Validation of a Patient-assessed Disease Activity Index in Systemic Sclerosis	36 799				
Hudson M.	Canadian Institutes for Health Research	Derivation and Validation of a Summary Score for the Medsger Disease Severity Scale		4 950			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Jagoe T.	McGill University	McGill University-gustavo Bounous Fund Postdoctoral Fellow at the Cancer Nutrition-rehabilitation Program		50 000			
Johnson, N.	Sir Mortimer B. Davis Jewish General H	N/a	14 500				
Kahn S.	Canadian Institutes for Health Research	Prospective Evaluation of Long-term Outcomes after Pulmonary Embolism: The ELOPE Study.	144 764				
Kahn S.	Fonds de la recherche en santé du Québec	Subvention au volet de soutien à la recherche clinique en partenariat avec l'industrie biopharmaceutique 2010-2011 - Composante de soutien stratégique aux centres de recherche	124 554				
Kahn S.	Canadian Institutes for Health Research	CIHR-a Randomized, Placebo-controlled Trial of Compression Stockings to Prevent the Post-thrombotic	112 546				
Kahn S.	Canadian Institutes for Health Research	Dalhousie University - Extended Prophylaxis Comparing Low Molecular Weight Heparin (LMWH) to Aspirin in Total Hip Arthroplasty (EPCAT Study)	34 100				
Kahn S.	National Institutes of Health (USA) NIH	Suresh Vedantham -University of McMaster - Pharmacomechanical Catheter-directed Thrombolysis for Acute DVT-attract Trial	10 062				
Kahn S.	Lawson Health Research Institute	A Prospective Study of Upper Extremity Deep Vein Thrombosis to Determine the Prevalence of Post-thrombotic Syndrome in Patients Managed with Anticoagulation.	8 500				
Kahn S.	Heart and Stroke Foundation of Ontario	P. Wells - HSFO - Development and Validation of Clinical Prediction Rules for Bleeding for Patients on Anticoagulant Therapy for Venous Thromboembolism	2 580				
Kahn S.	The Ottawa Heart Research Institute Corp	CIHR 524E-CVD-9101-004 - TIPPS (Thrombophilia in Pregnancy Prophylaxis Study): A Multicentre, Multinational Randomised Control Trial of Prophylactic Low Molecular Weight Heparin (LMWH) in High Risk Pregnant Thrombophilic Women	500				
Kahn S.	Heart and Stroke Foundation of Ontario	Thrombosis in Family Members of Patients with Unprovoked Venous Thromboembolism	300				
Karaplis A.	Canadian Institutes for Health Research	Pthrp and Osteoblast Biology: Relevance to Osteoporosis	164 201				
Karaplis A.	Kidney Foundation of Canada	Hormonal and Molecular Regulation of Phosphorus Homeostasis	37 313				
Karaplis A.	Canadian Institutes for Health Research	CIHR-group in Medical Genetics-Rima Rozen	16 560				
Kleiman L.	National Institutes of Health (USA) NIH	Development of the Gag/lysRS Interaction as a Target for Anti-HIV Therapy	621 409				
Kleiman L.	Canadian Institutes for Health Research	Formation of the tRNALys Packaging Complex in HIV-1	148 274				
Kleiman L.	Canadian Institutes for Health Research	Annealing of Primer tRNA Lys-3 to Genomic RNA in HIV-1.	72 542				
Kleiman S.	Fresenius Kabi	Jewish General Hospital Anesthesia Fellowship	15 000				
Koromilas A.	National Cancer Institute of Canada	Renewal - Functional Interaction Between the IFN-inducible Protein Kinase PKR and the Tumor Suppressor P53: Implications in Cell Growth Control	141 000				
Koromilas A.	Canadian Institutes for Health Research	Control of PI3K Signaling by the eIF2Alpha Kinase PKR: Implications in mRNA Translation, Cell Proliferation and Virus Replication	114 144				
Koromilas A.	Cancer Research Society	Characterization of eIF2A Kinases as Novel Targets of Oncogenic Signaling in Breast Tumorigenesis with Therapeutic Potential	96 728				
Koromilas A.	Leukemia Research Fund of Canada	Oth-Koromilas-Leukemia Lymphoma Society	60 000				
Koromilas A.	The WeekEnd to Breast Cancer	Mechanisms of VSV-mediated Oncolysis in ErbB2-transformed Cells	40 000				
Koromilas A.	Canadian Institutes for Health Research	CIHR-Koromilas A.-Papadakis CGD-96422		35 000			
Koromilas A.	Canadian Institutes for Health Research	Regulation of HIF-1alpha Phosphorylation by the eIF2Alpha Phosphorylation Pathway		6 000			
Koromilas A.	Canadian Institutes for Health Research	The eIF2 Alpha Kinase PKR as a Molecular Switch Between Cell Survival and Cell Death		2 500			
Leblanc A.	National Institutes of Health (USA) NIH	Phosphorylation of Prion Protein as a Novel Mechanism for Conversion	127 541				
Leblanc A.	Canadian Institutes for Health Research	Role of Caspases in Human Neuronal Cell Death and in Alzheimer's Disease	123 418				
Leblanc A.	Canadian Institutes for Health Research	Regulation of Prion Protein Expression, Trafficking and Function	106 137				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Leblanc A.	Canadian Institutes for Health Research	Structure-function Analyses of Caspase-6	27 500				
Leblanc A.	Canada Foundation For Innovation	CFI	8 132				
Leblanc A.	Institut universitaire de gériatrie de Mtl	Nouveaux modèles de la maladie d'alzheimer dans le poisson zèbre	4 000				
Leblanc A.	Canadian Institutes for Health Research	Neuroinflammation CIHR Strategic Training Program		20 000			
Lehoux S.	Canadian Institutes for Health Research	CIHR-Athero-Protective Shear Stress Signalling in the Vasculature	102 183				
Lehoux S.	Secrétariat des Chaires de rech du Canada	Cardiovascular Physiology	97 644				
Lehoux S.	Centre hospitalier univ de Québec(CHUQ)	Transformation des EPC pour stopper la resténose	39 300				
Liang C.	Canadian Institutes for Health Research	Studying the Antiviral of Bone Marrow Stromal Cell Antigen 2 and the Countering Mechanism from HIV-1 Vpu	144 269				
Liang C.	Canadian Institutes for Health Research	Exploring the Involvement of RNA Helicases in HIV-1 Replication.	55 652				
Liang C.	Canadian Institutes for Health Research	Fragile X Mental Retardation Protein Targets HIV-1: from Fragile X Syndrome to Aids	52 009				
Liang C.	Canadian Institutes for Health Research	Fusion and Cell Entry by Oncogenic Sheep Retroviruses	25 000				
Lin R.	Canadian Institutes for Health Research	Hepatitis C Virus Replication and Interferon Signaling	174 307				
Lin R.	Ministère du développement économique, d	RIIV: Réponse immunitaire innée et infection virale dans le domaine des sciences de la vie (Immunologie-infectiologie)	43 478				
Lin R.	Canadian Institutes for Health Research	Small Molecule Agonists of the RIG-I Pathway as Innate Stimulatory Agents Against Influenza Virus Infection	33 200				
Mann K.	National Institutes of Health (USA) NIH	The Role of LXR/RXR Heterodimers in Arsenic-induced Atherosclerosis.	106 306				
Mann K.	Canadian Institutes for Health Research	Mechanisms of Arsenic-enhanced Atherosclerosis	100 000				
Mann K.	Leukemia Research Foundation	Oth-Mann-Leukemia Research Foundation	76 503				
Mann K.	The Week-End to Breast Cancer	Combination Therapies to Overcome mTOR Inhibitor-induced Survival Signals	950				
Michel, C.	Aventis Pharma Canada	Heart Failure Clinic Equipment Donation	81 576				
Michel, C.	National Institutes of Health (USA) NIH	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients	23 710				
Michel, C.	Canadian Institutes for Health Research	Étude du suivi des patients vus en urgence hospitalière pour insuffisance cardiaque congestive (IC): comparaison de ceux qui sont orientés vers les cliniques spécialisées et de ceux qui ne le sont pas	14 975				
Miller W.	McGill University	McGill Integrated Cancer Research Training Program	228 333				
Miller W.	Canadian Institutes for Health Research	Mechanisms of Anti-cancer Action of Arsenic and Antimony	173 331				
Miller W.	National Cancer Institute of Canada	The Role of ROS in the Enhanced Tumor Specificity of Arensice when Combined with the Vitamin E-derivative Trolox	155 379				
Miller W.		Mechanisms of Response and Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.	138 305				
Miller W.	AACR	Targeting Eif4E with Ribavirin in Poor Prognosis Breast Cancer	101 961				
Miller W.	CUSM-Centre universit. de santé Mcgill	CIHR - Brian Ward - Molecular Mechanisms of Retinoids as Anti-virals in Respiratory Virus Infections	53 000				
Miller W.	McGill University	James McGill Professorship - Novel Cancer Therapeutics - Operating Funds	30 000				
Miller W.	Samuel Waxman Cancer Research Foundation	Development of Novel Anti-cancer Therapies Using Arsenic Trioxide	20 220				
Miller W.	Gerber Foundation	University of Arizona - The Role of Tungsten in Four Leukemia - Associated Areas in the Western United States	15 527				
Miller W.	The Cole Foundation	Cole Foundation Fellowship		45 500			
Mouland, A.	Canadian Institutes for Health Research	Virus-host Interactions and HIV-1 Pathogenesis: Studies on HNRNP A2-mediated HIV-1 RNA Trafficking	109 807				
Mouland, A.	Canadian Institutes for Health Research	Understanding How the HIV-1-Dependent Ribonucleoprotein Counters Host Stress Responses	105 062				
Mouland, A.	Canadian Foundation For Aids Research	Implications of Upframeshift Suppressor Protein 1 (UPF1) in HIV-1 Genomic RNA Fate	80 000				
Mouland, A.	Canadian Institutes for Health Research	Intéactions virus-hôte régulant le sort de l'ARN du VIH-1.		15 750			
Mouland, A.	Canadian Institutes for Health Research	Studies on the Importance of Heterogeneous Nuclear Ribonucleoprotein A2 in the Cell-to-cell Transmission of HIV-1 in T Cells.		1 750			

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Panasci L.	Canadian Institutes for Health Research	C-abl-directed Molecular Re-engineering of Chlorambucil to Offer New Therapeutic Options to Patients with Chronic Lymphocytic Leukemia (CLL)	18 705				
Panasci L.	National Cancer Institute of Canada	Sorafenib in Breast Cancer: a Laboratory-based Approach For a Rational Clinical Development. (Post-MD Research Fellowship)		47 500			
Panasci L.	Canadian Institutes for Health Research	CIHR/r&d-Wyeth Pharmaceuticals Research Program - Synergistic Effect of DNA-PK Inhibitors in the Treatment of Colon Cancer		45 000			
Pantopoulos K	Canadian Institutes for Health Research	The Role of Soluble Hemojuvelin in Systemic Iron Homeostasis	154 672				
Pantopoulos K	Canadian Institutes for Health Research	Iron Metabolism in Health and Disease: The IRE/IRP System and Beyond	128 656				
Pantopoulos K	Natural Sci & Engineering Res Council	Iron Metabolism and Hepatitis C Virus (HCV) Repliation	44 227				
Paudel H.	Parkinson's Foundation of Canada	Parkinson's Disease		12 500			
Paudel H.	McGill University	Phosphorylation of Protein Phosphatase 1 during Neuronal Differentiation	35 237				
Paudel H.	Alzheimer Society of Canada	ASC/FRSQ Award - Pathogenic Tau Mutations and Neurodegeneration		1 669			
Paudel H.	Alzheimer Society of Canada	EGR-1 and Alzheimer's Disease	56 250				
Paudel H.	Alzheimer Society of Canada	Alzeimer Society Research Program Doctoral award		10 515			
Paudel H.	Canadian Institutes for Health Research	Tau Protein and Alzheimer's Disease	134 809				
Pepe Carmela	Canadian Institutes for Health Research	Raising Lung Cancer Awareness One Breakthrough at a Time	3 000				
Pollak M.	National Institutes of Health (USA) NIH	NIH - IGF and Breast Cancer	233 959				
Pollak M.	National Cancer Institute of Canada	Canadian Breast Cancer Research Initiative - Modifiable Dietary Determinants of Levels of IGF-1, Insulin, and Risk of Colorectal Cancer and Lethal Prostate Cancer	138 833				
Pollak M.	Prostate cancer foundation	Prevention of Treatment and Disease-related Morbidity during Androgen Deprivation Therapy: a Multicenter Proposal	102 600				
Pollak M.	Sir Mortimer B. Davis Jewish General Hosp.	A Pilot Clinical Trial of Metformin in Prostate Cancer	40 000				
Pollak M.	Cancer de la prostate Canada	PTEN Loss and Energy Metabolism in Prostate Cancer	30 000				
Pollak M.	National Cancer Institute of Canada	Dietary Factors Influencing IGF-signaling in Prostate Cancer	25 420				
Pollak M.	American Cancer Society	Master Service Agreement # 9829	9 840				
Pollak M.	Provincial Health Services Authority	CPCRI - Does Insulin Resistance Increase Risk of Prostate Cancer? Assay Work. (NCIC with Richard Gallegher)	4 784				
Pollak M.	Canadian Institutes for Health Research	Pharmacokinetics of Insulin Signaling in Normal Versus Neoplastic Tissue in Vivo		35 000			
Ponka P.	Canadian Institutes for Health Research	1- Regulation of Iron Metabolism and Heme Synthesis in Erythroid Cells	131 163				
Ponka P.	Canadian Institutes for Health Research	Chelation, Mobilization and Metabolism of Storage Iron	104 213				
Richard S B.	Ministère du développement économique, d	CiPhER: Consortium international pour l'identification des gènes de fracture osteoporotique	200 586				
Richard S B.	Canadian Institutes for Health Research	Genetic Epidemiology of Osteoporotic Fractures. From Susceptibility Genes to Susceptible Populations	131 260				
Richard S B.	Agence de santé publique du Canada ASPC	Genetic Determinants of 25-hydroxy Vitamin D Levels	89 499				
Richard S B.	Fonds de la recherche en santé du Québec	Établissement de jeune chercheur - épidémiologie génétique des fractures osteoporotiques: des gènes de susceptibilité aux populations susceptibles	10 000				
Richard S B.	Canadian Institutes for Health Research	Genetic and Environmental Determinants of Vitamin D Levels in Canadians		45 000			
Richard S B.	Canadian Institutes for Health Research	Genetic Epidemiology of Osteoporotic Fractures: from Susceptibility Genes to Susceptible Populations		45 000			
Richard S B.	Canadian Institutes for Health Research	The Role of Rare Genetic Variants in Common Disease		28 333			
Richard S.	Canadian Institutes for Health Research	Arginine Methylase PRMT1 and PRMT6 in Cancer and Genomic	175 420				
Richard S.	Canadian Institutes for Health Research	Role of the Star RNA Binding Protein Sam68 in Regulating Cell Migration and Proliferation in Cancer	156 661				
Richard S.	Canadian Institutes for Health Research	The Role of Arginine Methylation MRE11 in Mediating the DNA Damage Response	137 473				
Richard S.	National Cancer Institute of Canada	The Role of the Quaking RNA Binding Proteins in Tumorigenesis	123 000				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Richard S.	Multiple Sclerosis Society of Canada	The Role of the Quaking Protein in Signal Transduction and RNA Metabolism.	84 770				
Richard S.	The WeekEnd to Breast Cancer	The Role of Lysine Methylation in BRCA-dependent DNA Damage Signaling	40 000				
Richard S.	The WeekEnd to Breast Cancer	Targeting the Breast Tumor Kinase (BRK) in Breast Cancer Therapy	551				
Richard S.	Cancer Research Society	Investigation of Sam68-like Mammalian Proteins, SIm-1 and SIm-2, in Human Cancers	(1 514)				
Richard S.	Canadian Institutes for Health Research	Lysine Methylation of Non-histone Proteins		45 000			
Richard S.	Canadian Institutes for Health Research	The Role of Protein Demethylases in the DNA Damage Response		45 000			
Richard S.	Multiple Sclerosis Society of Canada	Study MicroRNA and Quaking RNA Binding Protein Function on Oligodendrocyte Differentiation		19 500			
Richard S.	Multiple Sclerosis Society of Canada	Identification of the Quaking RNA Targets		4 500			
Richard S.	Multiple Sclerosis Society of Canada	QKI Myelination		4 500			
Rudski, L.	Sir Mortimer B. Davis Jewish General Hosp.	Avi Shimony - Azrieli Fellow		50 000			
Schiffirin, E.	Canadian Institutes for Health Research	Role of Endothelin in Hypertension and Vascular Injury	173 810				
Schiffirin, E.	Canadian Institutes for Health Research	CIHR-T-regulatory Cells and Vascular Injury in Hypertension	123 047				
Schiffirin, E.	Canadian Institutes for Health Research	Vascular Remodeling in Hypertension: from Genes to Mice to Humans	116 432				
Schiffirin, E.	McGill University	Dean's Funds - Vascular Phenotype Infrastructure: Molecular and Cellular Mechanisms of Vascular Remodeling In Hypertension and Metabolic Syndrome.	30 500				
Schiffirin, E.	Heart & Stroke Foundation Canada	Remodelage des artères de petit et gros calibre dans l'insuffisance rénale chronique		40 000			
Schiffirin, E.	Regroupement Compagn. Fond. et particul.	Azrieli Foundation Fellowship		25 000			
Schipper H.	Canadian Institutes for Health Research	Role of Heme Oxygenase-1 in Aging and Parkinsonian Neural Tissues	136 571				
Schipper H.	Grouping of Canadian Individuals	MKCF Research	50 000				
Schipper H.	Molecular Biometrics, LLC	Neurodegenerative Disease Spectroscopy	25 218				
Sebag I.	Massachusetts General Hospital	Susan G. Komen Breast Cancer - Early Detection and Prediction of Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients (Project)	12 911				
Sheppard, R.	Institut de cardiologie de Montréal	Dr. Jean Rouleau - CARRESS - Cardiorenal Rescue Study in Acute Decompensated Heart Failure	20 500				
Suissa S.	Canadian Institutes for Health Research	Canadian Network for Observational Drug Effect Studies (CNODES)	875 000				
Suissa S.	Grouping of Canadian Individuals	Priv-Suissa S.-pharmacoepidemiology	63 440				
Suissa S.	Canadian Institutes for Health Research	Multiple Medication Use in the Quebec Elderly and the Risk of Motor Vehicle Crash	43 787				
Suissa S.	Cancer de la prostate Canada	Pilot Grant	30 000				
Szilagyi A.	Institut Danone	Differential Biologic Impact of Lactose Consumption in Lactase Persistent and Non-persistent Population	100				
Tagalakis, V	Eisai Research Institute	Dalteparin Sodium Injection (Fragmin), Multi-center, Open Label, Single-arm, Controlled Long-term (53 Weeks) Study For Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Thromboembolism	31 587				
Tagalakis, V	Heart & Stroke Foundation Quebec	Screening for Previously Undiagnosed Malignancy in Patients with Unprovoked Venous Thrombembolism: a Randomized Controlled Trial Using a Comprehensive Computed Tomography of the Abdomen/pelvis	19 750				
Thombs, B.	Canadian Institutes for Health Research	Will Routine Depression Screening Benefit Patients in Cardiovascular Care Settings? An Updated Systematic Review	92 989				
Thombs, B.	Canadian Institutes for Health Research	Will Screening for Distress Improve Patient Well-being in Cancer? A Systematic Review	88 489				
Thombs, B.	Fonds de la recherche en santé du Québec	Développement et validation d'un système intégré pour évaluer la fatigue liée a la sclérodermie	65 946				
Thombs, B.	American College of Rheumatology	ACR Research and Education Foundation Arhp Investigator Award	50 780				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Thombs, B.	Canadian Institutes for Health Research	Consortium for Behavioural, Psychological, and Educational Trials in Scleroderma	18 400				
Thombs, B.	Grouping of Canadian Comp. and Corp.	Operating Grant	10 758				
Thombs, B.	Canadian Institutes for Health Research	Depression Screening and Patient Outcomes in Pregnancy and Postpartum: a Systematic Review	(6 178)				
Thombs, B.	Canadian Institutes for Health Research	Development and Validation of a Fatigue Assessment Protocol for Scleroderma		17 500			
Thombs, B.	Canadian Institutes for Health Research	Improving Depression Screening in Rheumatology Clinics: Detection of Persistent Versus Acute Depression in Scleroderma Patients		17 500			
Thombs, B.	Canadian Institutes for Health Research	Prevalence of Major Depression in Patients with Cardiovascular Disease: a Meta-analysis of the Role of the Method in Depression Assessment		17 500			
Thombs, B.	Fonds de la recherche en santé du Québec	Etablissement de jeune chercheur - La sclerodermie: un programme d'étude portant sur l'expérience de la maladie selon la perspective des patients		15 000			
Thombs, B.	Canadian Institutes for Health Research	CIHR		4 950			
Thombs, B.	Canadian Institutes for Health Research	Development and Validation of a Pruritus Measure for Patients with Systemic Sclerosis		4 950			
Tischkowitz, M.	The WeekEnd to Breast Cancer	Ten Genes for Hereditary Breast Cancer - Estimating the Contribution of Breast Cancer Genes in Quebec Hereditary Breast Cancer Families	39 737				
Tischkowitz, M.	Susan G. Komen Breast Cancer Foundation	Palb2 - A New Hereditary Cancer Gene: Implications for Treatment	29 056				
Trifiro M.	Canadian Institutes for Health Research	Innovative Approaches to Functional Characterization of the Androgen Receptor in Prostate Cancer	58 462				
Trifiro M.	McGill University	Thyroid Tumor Study Group-ent/thyroid	40 640				
Trifiro M.	Canadian Institutes for Health Research	Implantable Device for Early Detection of Orthopaedic Infection	11 500				
Trifiro M.	The WeekEnd to Breast Cancer	Non-biological Targeted Therapy for Breast Cancer	10 000				
Trifiro M.	McGill University	McGill / GSK Lecture on Metabolism	5 000				
Trifiro M.	Canadian Institutes for Health Research	CIHR - Rima Rozen - MRC Group in Medical Genetics	1 190				
Trifiro M.	Grouping of Foreign Individuals	Diabetes Research	139				
Wainberg M.	Laboratoire de santé publique	Phase 2 - Infrastructures pour la recherche sur l'infection au VIH: doter le Québec et le Canada d'infrastructures pour un vaccin et des thérapies contre le VIH et l'hépatite C	310 436				
Wainberg M.	Canadian Institutes for Health Research	Out of 166,666\$ 3*40k\$ Should Be Redistributed to Kleiman, C. Liang, M.J. Tremblay (Quebec)	166 666				
Wainberg M.	Canadian Institutes for Health Research	Pro-active Intervention to Limit HIV Transmission among MSM Populations	140 308				
Wainberg M.	Canadian Institutes for Health Research	Patterns of Drug Resistance and Viral Evolution in Patients Undergoing Primary HIV-1 Infection	128 550				
Wainberg M.	Canadian Institutes for Health Research	Studies on HIV Integrase as Key Components of Effective Therapy: Molecular Pathogenesis Studies	118 051				
Wainberg M.	Canadian Institutes for Health Research	Methylation of HIV Viral Proteins as Key Steps in Viral Replication	111 191				
Wainberg M.	Canadian Institutes for Health Research	The Impact of HIV Drug Resistance Mutations in Different Viral Subtypes on Viral Fitness and Phenotype	100 000				
Wainberg M.	Canadian Institutes for Health Research	Individual/group Grant - Identification of Novel Targets To Interfere with HIV Reverse Transcriptase and Viral Multiplication	78 959				
Wainberg M.	Fonds de la recherche en santé du Québec	Réseau SIDA et maladies infectieuses	78 300				
Wainberg M.	Canadian Foundation For Aids Research	Are There HIV-1 Subtype Specific Differences in Resistance to Integrase Inhibitors?	78 000				
Wainberg M.	University of Michigan	James Koopman - NIH-HIV Risk Dynamics, Genetic Patterns and Control	73 238				
Wainberg M.	Canadian HIV Trials Network	Oth-Wainberg M.-Sloan R-CCRs Co-receptor	50 000				
Wainberg M.	Canadian Institutes for Health Research	The Botswana-canada AIDS Vaccine Discovery Partnership	25 000				
Wainberg M.	Fonds de la recherche en santé du Québec	Coordination réseau SIDA et maladies infectieuses	20 000				

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Wainberg M.	Fonds de la recherche en santé du Québec	Analyse moléculaire	13 500				
Wainberg M.	Canadian Institutes for Health Research	Addition of Exogenous Tat during Early Infection to Inhibit the Establishment of Latency		35 000			
Wainberg M.	Canadian Institutes for Health Research	Defining Effective Anti-viral Combinations in Order to Decrease the Sexual Transmission of HIV		35 000			
Wainberg M.	Canadian Institutes for Health Research	The Contribution of Cellular PRMT6 to HIV-1 Pathogenesis		20 250			
Wainberg M.	Canadian Institutes for Health Research	Étude de l'impact des nouvelles molécules antirétrovirales sur les sous-types non B de VIH-1, importance des nouvelles mutations et des populations minoritaires portant des mutations de résistance		3 333			
Wainberg M.	Canadian Institutes for Health Research	Study of Complex Pharmacogenomicpharmacokinetics: Host-pathogen Interactions: Application to HIV Disease		(11 562)			
Wassmann S.	Canadian Institutes for Health Research	Role of At1 Receptor Activation in Progenitor Cell Biology, Endothelial Regeneration, Atherosclerosis, Insulin Resistance, and Adipogenesis	79 376				
Wassmann S.	Secrétariat des Chaires de rech du Canada	CRC-mechanisms Invovled in Endothelial Damage and Regeneration	51 790				
Wu, J.H.	Canadian Institutes for Health Research	Novel Bifunctional Antiandrogens That Supress Oncogenic Activation of the Androgen Receptor in Castration-resistant Prostate Cancer	159 750				
Wu, J.H.	Cancer Research Society	Development of Bifunctional Antiandrogens That Suppress Oncogenic Activation of the Androgen Receptor in Castration-resistant Prostate Cancer	45 000				
Wu, J.H.	Sir Mortimer B. Davis Jewish General Hosp.	Seed Money from the JGH Foundation (- Brojde Foundation) on Research Projects Related to Chinese Herbs and Lung Cancer	36 000				
Wu, J.H.	Canadian Institutes for Health Research	Chemical Inhibitors of Androgen Receptor Splice Variants Lacking the Ligand-binding Domain as Novel Agents for Castration-resistant Prostate Cancer	24 391				
Zaharatos J.	Aaron Diamond Aids Research Cntr (ADARC)	David D - Harnessing Dendritic Cells and Innate Immune Activation Signals to Guide HIV Vaccine Development	63 040				
Lehoux S.	McGill University	McGill University - CFI-CRC-vascular Signaling and Function	5 231				
Jagoe T.	Canada Foundation For Innovation	Mechanism of Muscle Wasting in Clinical Cancer Cachexia: New Experimental Approaches and Models for Testing Anti-cachexia Therapies	98 466				
Mann K.	Canada Foundation For Innovation	Mechanisms of Metal-induced Toxicity	122 459				
Richard S B.	Canada Foundation For Innovation	McGill University - A Laboratory to Study the Genetic Epidemiology of Aging-related Disease	86 354				
Wassmann S.	Canada Foundation For Innovation	CFI - Mechanisms Involved in Endothelial Damage and Regeneration	203 108				
JGH Foundation (including designated donations, bequests and endowments)							
Baron M.	Grouping of Canadian Individuals	Rheumatology Research					15 226
Baron M.	Grouping of Canadian Comp. and Corp.	Registry - Arthritis					6 815
Batist G.	Grouping of Canadian Individuals	Translational Research Center					332 488
Batist G.	Grouping of Canadian Individuals	Oncology Research					313 897
Batist G.	Grouping of Canadian Individuals	Equipment Purchases					137 052
Batist G.	Grouping of Canadian Individuals	Retreats and Conferences					95 000
Batist G.	Grouping of Canadian Individuals	Cytometry Fees					5 868
Batist G.	Grouping of Canadian Individuals	Experimental Therapeutics					1 101
Batist G.	Grouping of Canadian Individuals	Research Pathology Facility					571
Batist G.	Grouping of Canadian Individuals	Imaging Facility					270
Becker R.	Grouping of Canadian Individuals	Internal Medicine Research					179

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Bergman H.	Grouping of Canadian Individuals	Réseau québécois de recherche sur le vieillissement - programme d'aide à la formation de chercheurs-cliniciens en gériatrie					15 000
Billick R.	Grouping of Canadian Individuals	Dermatology Research					1 333
Caplan S.	Grouping of Canadian Individuals	Hematology Research					309 923
Chertkow H.		Cognitive Research					574
Chong	Grouping of Foreign Individuals	Inv-Chong -Special Purchases					49 500
Cohen A.	Grouping of Canadian Individuals	Inflammatory Bowel Disease					104 622
Cohen A.	Grouping of Canadian Individuals	Gastroenterology Research					10 048
Dept of Medicine	Grouping of Canadian Individuals	Medicine R&D					62 121
Dragatakis L.	Grouping of Canadian Comp. and Corp.	Cath Lab Education Fund					2 250
Eisenberg M.	Grouping of Canadian Individuals	Inv-Eisenberg Special Purchases					55 000
Elizov, M.	Grouping of Canadian Individuals	Dr. M. Elizov -Medical Residents					20 000
Foulkes W.	Grouping of Canadian Individuals	Surgical Research					32 320
Friedman, Ruby	Grouping of Canadian Individuals	Memory Clinic					39 035
Friedman, Ruby	Grouping of Canadian Individuals	Geriatrics Research					31 736
Friedman, Ruby	Grouping of Canadian Individuals	Geriatric Research					18 842
Greenaway C.	Grouping of Canadian Individuals	Department of Medicine Award					8 000
Jagoe T.	Grouping of Canadian Individuals	Cancer Nutrition Program CNRP					111 005
Kahn S.	Grouping of Canadian Individuals	Thrombosis Clinic					99 819
Karaplis A.	Grouping of Canadian Individuals	Dr.Karaplis-Fracture Prevention Clinic					37 000
Kavan P.	Grouping of Canadian Individuals	Young Adult Program					176 312
Khanna	Grouping of Canadian Individuals	Skin Cancer Research Fund					13 171
Kleiman S.	Grouping of Canadian Individuals	Oth -S Kleiman- Anesthesia Therapist Ed.					1 400
Langleben D.	Grouping of Canadian Individuals	Cardiology Research					239 140
Langleben D.		Dr. Langleben -Ph Clinic					785
Laporta D.	Grouping of Canadian Individuals	Oth-Laporta ICU Research					1 015
Lipman M.	Grouping of Canadian Individuals	Hemodialysis Research					196 459
Lipman M.	Grouping of Canadian Individuals	Renal Research					7 514
Tamilia, M	Grouping of Canadian Individuals	Thyroid Tumor Research					4 521
Miller M.	Grouping of Canadian Individuals	Infectious Diseases Research					158
Miller W.	Grouping of Canadian Individuals	8th Int.Conference of Differentiation Therapy - Mtl, QC Oct.3-6, 1999					20 764
Monette J.	Grouping of Canadian Foundations, Associ	Collaborative Research at Maimonides					37 652
Panasci L.	Grouping of Canadian Individuals	Donations.					21 782
Pollak M.	Grouping of Canadian Individuals	CPRU - Stroll - Cancer Screening					55 608
Pollak M.	Grouping of Canadian Individuals	Breast Cancer Research					15 612
Portnoy J.	Grouping of Canadian Individuals	Dr. Portnoy-Campagne québécoise EAPSSS					190 750
Portnoy J.	Grouping of Canadian Individuals	Infectious Disease Research					6 331
Richard S.	Grouping of Canadian Individuals	Inv-Richard RNA Binding					352
Rudski, L	Grouping of Canadian Individuals	Inv-Rudski - Eco Training Fund					8 800
Schiffirin A.	Grouping of Canadian Individuals	Diabetes Research					9 818
Schiffirin, E.	Grouping of Canadian Individuals	Dr.E.Schiffirin- DG. Dept. Medecine Endow					20 534
Schiffirin, E.	Grouping of Canadian Individuals	Cardiovascular Prevention Centre					18 831
Schiffirin, E.	Grouping of Canadian Individuals	Dr. E. Schiffirin - DG.Dep.Med.Endow (Auxil.)					3 886
Schipper H.	Grouping of Canadian Individuals	Dr. Schipper H.- MKCF-clinic					50 000
Schipper H.	Grouping of Canadian Individuals	Alzheimer's Research					140
Schweitzer M.	Grouping of Canadian Individuals	Lipid Research					45 000
Schweitzer M.	Grouping of Canadian Individuals	Cardiac Endocrinology Research					4 216
Schweitzer M.	Grouping of Canadian Individuals	Cardiovascular Risk Research					31
Small D	Grouping of Canadian Individuals	Pulmonary Research					162 169
Small D	Grouping of Canadian Individuals	Pulmonary Academic Enrichment (Pae).					12 000
Therrien	Grouping of Canadian Individuals	Cardiology Research					34 861

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Trifiro M.	Grouping of Canadian Individuals	Endocrinology Research and Development					87 801
Trifiro M.	Grouping of Canadian Individuals	Genetics Research					85 275
Trifiro M.	Grouping of Canadian Individuals	Insulin Fund					12 327
Trifiro M.	Grouping of Canadian Individuals	Oth-Trifiro M.-Tamila					10 250
Trifiro M.	Grouping of Canadian Individuals	Endocrinology Research					3 041
Trifiro M.	Grouping of Canadian Individuals	Medical Genetics Research					378
Wainberg M.	Grouping of Canadian Individuals	AIDS Research					21 647
Wainberg M.	Grouping of Canadian Individuals	Inv-Wainberg AIDS Project					16 787
Wainberg M.	Grouping of Canadian Individuals	Québec Conference					435
Warshawsky, P.	Grouping of Canadian Individuals	ICU Surgical Research					18 458
							0
Industrial Contracts							
Agulnik J.	Boehringer-Ingelheim Canada Ltd.	Multi-center, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF1120 plus Standard Pemetrexed Therapy Compared to Placebo plus Standard Pemetrexed Therapy in Patients with Stage IIIb/IV or Recurrent non ...			119 756		
Agulnik J.	Boehringer-Ingelheim Canada Ltd.	Multi-country, Retrospective, Cross-sectional Chart Review of Patients with Advanced NSCLC			49 000		
Agulnik J.	Boehringer-Ingelheim Canada Ltd.	Multi-country, Cross-sectional, Prospective Quality of Life Survey of Patients with Advanced NSCLC			3 500		
Agulnik J.	Genentech Inc.	A Randomized, Double-blind, Phase II Trial of Paclitaxel + Carboplatin + Bevacizumab with or Without Apomab in Patients with Previously Untreated, Advance-stage Non-small Cell Lung Cancer			2 200		
Agulnik J.	Genentech Inc.	A Randomized, Phase II, Multi-center, Double-blind, Placebo-controlled Study Evaluating the Safety and A<+>ctivity of Metmab a Monovalent Antagonist Antibody to the Receptor Met, Administered to Patients with Advanced Non-small Cell Lung Cancer, I			(10 320)		
Assouline S.	Novartis Pharma Canada Inc.	A Randomized Phase II Study of Oral Panobinostat (Lbh589) with or Without Rituximab to Treat Relapsed or Refractory B-cell Non-hodgkin Lymphoma			151 656		
Assouline S.	Hoffman-La Roche Ltd., Canada	Ph*-Assouline S.-Roche/prot N. BP22333			13 875		
Baron M.	Actelion Pharmaceuticals Canada Inc.	A Two-stage Prospective Observational Cohort Study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension and Pulmonary Hypertension			27 092		
Baron M.	United Therapeutics Corporation	Distol-1: Digital Ischemic Lesion in Scleroderma Treated W Oral Treprostinil Diethanolamine (Protocol: Tde-du-201)			15 518		
Baron M.	Amgen Canada Inc.	Canadian Methotrexate and Ethanercept Outcome Study: an Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis Cameo			8 618		
Baron M.	Services d'analyse de risque QSAR Inc.	Ph*Baron-CRR:PGRX Mai-prot.#MP-JGH-08113			7 750		
Baron M.	United Therapeutics Corporation	Distol-ext: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine:			5 872		
Baron M.	Pfizer Canada Inc.	A Phase 2a Randomized Double-blinded, Placebo and Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study to Asses Efficacy of a Once Daily Administration of a Phosphodiesterase 5 Inhibitor (Pf-00489791) for the Treatment of Vasospas			5 831		
Baron M.	Abbott Laboratories Canada	Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking Humira			4 000		
Baron M.	Grouping of Canadian Individuals	A Multicenter, Open Label Study to Describe the Safety of Daily Subcutaneous Injections of Anakinar (R-methuil-1ra) In Patients with Rheumatoid Arthritis.			2 070		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Baron M.	JSS Medical Research Inc.	Optimization of Treatment with Adalimumab (Humira), a Multi-center, Randomize, Single Blind, Controlled Clinical Trial.			1 300		
Batist G.	Pfizer Canada Inc.	Phospho-nrf2 as a Novel Biomarker for Identifying Patients for PI3k-mTOK Inhibition to Achieve Selective Chemosensitization			200 000		
Blostein M.	Bristol-Myers Squibb Inc. Canada	A Phase 3, Active (Warfarin) Controlled, Randomized, Double-blind, Parallel-arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation. CV185030			77 972		
Boutet K.	Millennium Pharmaceutical Inc.	Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral Bay 63-2521 (1 Mg, 1.5 Mg, 2 Mg, or 2.5 Mg Tid) in Patients with Symptomatic Pulmonary Arterial Hypertension (Study 12934)			117 214		
Boutet K.	Bayer Inc. Health Care Division	Ph*Boutet-Pharbay 63-2521 Patent-2 Study			54 194		
Chertkow H.	Elan Pharmaceuticals Inc.	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E 4 Carrier			50 644		
Chertkow H.	National Institutes of Health (USA) NIH	University of California, San Diego - A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Vitamin E and Donepezil HCl (Aricept) to Delay Clinical Progression from Mild Cognitive Impairment (MCI)			37 195		
Cohen A.	Schering Corporation Ltd. USA	Screening for Hepatocellular Carcinoma			43 800		
Cohen A.	Abbott Laboratories U.S.A.	A Multi-center, Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Ulcerative Colitis			18 552		
Cohen A.	Millennium Pharmaceutical Inc.	Quintiles - A Phase 3, Randomized, Placebo-controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn's Disease			18 544		
Cohen A.	Abbott Laboratories Canada	A Phase IIb, Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Ranging			17 759		
Cohen A.	Quintiles Inc.	A Phase 3, Randomized, Placebo-controlled, Blinded, Multicenter, Multiple Dose Study for the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Ulcerative Colitis			6 978		
Cohen A.	Abbott Laboratories U.S.A.	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-tnf Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severly Active Ulcerative Colitis			3 279		
Cohen,V.	Novartis Pharma Canada Inc.	A Phase III, Randomized, Double-blind, Placebo-controlled Multi-center Study of ASA404 in Combination with Docetaxel In Second-line Treatment of Patients with Advanced or Metastatic (Stage IIIb/IV) Non-small Cell Lung Cancer (NSCLC)			13 579		
Cohen,V.	Pharmaceutical Research Associates Inc.	A Multi-center Phase III Randomized, Double-blind, Placebo-controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease			3 945		
CRU	Bayer Inc. Health Care Division	CRU - Phase I Open-label, Non-randomized Non-placebo Study to Determine the Safety, Pharmacokinetics, and Tumor Response Profile of Sorafenib as Continous Dosing in Combination with Cyclophosphamide and Doxorubicin in Patients with Advanced, Refr			205 486		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
CRU	Pfizer Canada Inc.	CRU - A Two-arm Randomized Open Label Phase 2 Study of CP-751,871 in Combination with Exemestane Versus Exemestane Versus Exemestane Alone as First Line Treatment For Postmenopausal Patients with Hormone Receptor Positive Advanced Breast Cancer			203 907		
CRU	Novartis Pharma Canada Inc.	A Phase Ia/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients with Advanced Non-hodgkin's Lymphoma Who Have Progressed after at Least Two Prior Therapies (CHCD122A2103)			178 511		
CRU	Ziopharm inc.	CRU - Phase I Study of Oral ZIO-101-c in Advanced Solid Tumors			132 420		
CRU	Wex Pharmaceuticals Inc.	CRU - A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy And Safety of Subcutaneous Tetrotoxin (Tectin) for Moderate to Severe Inadeuately Controlled Cancer-related Pain			100 708		
CRU	Infinity Pharmaceuticals Inc.	A Phase 1 Study of IPI-926 in Patients with Advanced and/or Metastatic Solid Tumor Malignancies			80 183		
CRU	Novartis Pharma Canada Inc.	Randomized, Open-label, Phase 3 Trial of Erlotinib Alone or in Combination with CP-751,871 in Patients with Advanced Non-small Cell Lung Cancer of Non-adenocarcinoma Histology			78 554		
CRU	Proteolix Inc.	CRU - an Open Label, Single Arm, Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)			59 105		
CRU	Pfizer U.S.A. Inc.	Phase I Safety and Tolerability Study of Figitumumab Combined with Pegvisomant in Patients with Adva			50 595		
CRU	Millennium Pharmaceutical Inc.	An Open-label, Dose-escalation, Phase 1 Study of MLN9708, a Second-generation Proteasome Inhibitor,			45 503		
CRU	Proteolix Inc.	Phase 1b Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Sa			39 081		
CRU	Hoffman-La Roche Ltd., Canada	CRU - an Open-label, Multi-centre, Dose Escalating, Phase I/II Study to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients with CD20+ Malignant Disease			36 295		
CRU	Oncozyme Pharma Inc.	CRU - A Phase I/II Clinical Study Using Pentamidine in Patients with Metastatic Colon Cancer Undergoing Standard Folinic Acid (Leucovorin), 5-fluoroucil, and Oxaliplatin (Folfox) Chemotherapy as Second-line Treatment			30 615		
CRU	Wex Pharmaceuticals Inc.	CRU - A Multi-centre, Open-label, Long-term Efficacy and Safety Continuation Study of Subcutaneous Tetrodotoxin (Tectin) for Moderate to Severe Cancer-related Pain			30 336		
CRU	Pfizer Canada Inc.	CRU - A Phase 2, Randomized,non-comparative, Two-arm Open Label, Multiple-center Study of CP-751,871 in Combination with Docetaxel/prednisone in Chemotherapy - Naïve (Arm A) and Docetaxel/prednisone Refractory (Arm B) Patients with Hormone			29 306		
CRU	Genentech Inc.	An Open-label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients with Rituximab-refractory, Indolent Non-hodgkin's Lymphoma			28 891		
CRU	Argos Therapeutic Inc.	CRU - A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib			27 760		
CRU	Aegera Theapeutics Inc.	AEG35156-204: a Phase 1-2, Multicenter, Open-label Study Of the X-linked Inhibitor of Apoptosis (Xiap) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, and Indolent B Cell Lymphomas			27 183		
CRU	Université de Montréal	CRU - A Phase II Study of Ribavirin in Refractory or Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes			26 315		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
CRU	Glaxosmithkline Inc. Canada	CRU - A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma			25 628		
CRU	Novartis Pharma Canada Inc.	CLBH589B2201 - A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-cell Lymphoma			18 623		
CRU	Celgene Corporation	A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomid			13 399		
CRU	Methylgene Inc.	CRU - A Phase II Study of MGCD0103 (MG-0103) Given Three-times Weekly in Patients with Relapsed and Refractory Lymphoma			12 230		
CRU	Pfizer Canada Inc.	CRU - A SU011248 Expanded Access Protocol for Patients with Cytokine-refractory or Cytokine-intole			11 752		
CRU	Hoffman La Roche Ltd., Canada	A Two-stage Phase 1b Study to Investigate the Pharmacokinetics, Safety and Tolerability of Rituximab			10 775		
CRU	GlaxoSmithKline Inc. Canada	CRU - Tra105325: Extend (Eltrombopag Extended Dosing Study): an Extension Study of Eltrombopage Olamine (SB-497115-gr) in Adults, with Idiopathic Thrombocytopenic Purpura (LTP), Previously Enrolled in an Eltrombopag Study			9 160		
CRU	Wyeth Canada	CRU - A Phase 2, Randomized, Open-label Study of Bosutinib Administerd in Combination with Exemestane vs. Exemestane Alone as Second Line Therapy in Post-menopausal Women with Locally Advanced or Metastatic ER+/PGR+/ERBB2-breast Cancer			9 125		
CRU	Bristol Myers Inc. Canada	CRU - CA184-024 - A Multicenter, Randomized, Double-blind, Two-arm, Phase III Study in Patient Wit			8 401		
CRU	Astra Zeneca Inc.	CRU - A Phase I, Open-label, Non-randomized Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, Recont), in Patients with Advanced Solid Tumors			8 000		
CRU	Wyeth Canada	CRU - A Phase 1/2 Study of SKI-606 in Philadelphia Chromosome Positive Leukemias			7 508		
CRU	Ziopharm inc.	A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Lus Palifosfamide-tris vs. Doxorubicin plus Placebo in Patients with Front-line Metastatic Soft Tissue Sarcoma. Tthe PICASSO III Study			5 665		
CRU	Zymogenetics	CRU - A Phase 1/2, Open-label, Dose-escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interluekin-21 Administered Concomitantly with Sorafenib (Nexavar) in Subjects with Metastatic Renal Cell Carcinoma			5 117		
CRU	Novartis Pharma Canada Inc.	CRU - an Open-label, Multicenter Phase 1 Study Investigating the Combination of Rad001, Cetuximab and Irinotecan as Second-line Therapy after Folfox (Or Xelox) Plus Bevacizumab (If Given as Part of Local Standard Practice) in Patients with Metasta			4 750		
CRU	GlaxoSmithKline Inc. Canada	CRU - A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in W			3 545		
CRU	Bayer Inc. Health Care Division	A Randomized, Double-blind, Placebo Controlled Phase III Study of Regorafenib plus BSC Versus Placebo plus BSC in Patients with Metastatic Colorectal Cancer (CRC) Who Have Progressed after Standard Therapy			2 952		
CRU	GW Pharmaceuticals plc	A Double-blind, Randomized, Placebo-controlled, Parallel Group Dose-range Exploration Study of Sativex in Relieving Pain in Patients with Advanced Cancer, who Experience Inadequate Analgesia during Optimized Chronic Opioid Therapy			2 818		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
CRU	Novartis Pharma Canada Inc.	A Canadian Open-label, Multicenter, Expanded Access Study Of Oral AMN 107 in Adult Patients with Imatinib (Glivec/gleevec) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase			1 750		
CRU	Wyeth Canada	CRU - Open-label Extension Study to Assess the Safety of a Fixed Dose of Subcutaneous Methylnatrexone in Subjects With Advanced Illness and Opioid-induced Constipation			1 000		
CRU	Wyeth Canada	CRU - Randomized, Double-blind, Placebo-controlled Study of a Fixed Dose of Subcutaneous Methylnatrexone in Adults with Advanced Illness and Opioid-induced Constipation: Efficacy, Safety, and Additional Health Outcomes			1 000		
CRU	Novartis Pharma Canada Inc.	Randomized, Open-label, Phase III Trial of CP-751, 871 in Combination with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin in Patients with Non-small Cell Lung Cancer			750		
CRU	Novartis Pharma Canada Inc.	CRU - CLBH589b2204 - A Phase Ib/IIa, Trial of LBH589 in Combination with Trastuzumab in Adult Female Patients with Her2 Positive Metastatic Breast Cancer Whose Disease Has Progressed during or Following Therapy with Trastuzumab			500		
CRU	MethylGene Inc.	CRU - A Phase II Study of MG-0103 in Patients with Acute Myelogenous Leukemia/high Risk Mds Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/refractory Disease			(15 581)		
Eisenberg M.	Canadian Institutes for Health Research	Genesis Praxy - Gender and Sex Determinants of Cardiovascular Disease: from Bench to Beyond Premature Acute Coronary Syndrome			2 750		
Gyger Martin	Janssen-Ortho Inc.	Velcade Observational Study			30 000		
Hilzenrat N.	Schering Corporation Ltd. Canada	Study P04257: Effect of Infliximab in Hepatitis-C Genotype 1 Patients with High TNF-Alfa on the Efficacy of Pegylated Interferon-Alfa 2/Ribavirin Therapy			15 823		
Hilzenrat N.	GlaxoSmithKline Inc. Canada	TPL108390: Randomised, Placebo-controlled, Multi-center Study to Assess The Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects with Hepatitis C Virus (HCV) Infection who are otherwise eligible to Initiate antiviral therapy			9 725		
Hilzenrat N.	Novartis Pharmaceuticals Corporation	Pharmacogenomic Analysis of Blood Samples to Identify Host Genomic Profiles that Segregate Responders from Non-responders Following Treatment with Peg-interferon and Ribavirin in HCV-infected Subjects (Genotype 1)			6 110		
Hilzenrat N.	Schering Corporation Ltd. Canada	Efficacy and Safety of 24 vs 48 Weeks of Pegatron (Peginterferon Alpha-2b + Ribavirin) Therapy (1.5 Mcg/kg/week + 800-1200 Mg/day) in Naive Genotype 1 Hepatitis C Patients with High Baseline Viral Load Who Are HCV-RNA Negative at Week 4 and Week 12			1 075		
Hilzenrat N.	Hoffman La Roche Ltd., Canada	A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological R			100		
Hirsch A.	Bayer Inc. Health Care Division	Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral Bay 63-2521 (1 Mg, 1.5 Mg, 2 Mg, or 2.5 Mg TID) in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)			50 961		
Hirsch A.	Bayer Inc. Health Care Division	Long-term Extension, Multi-centre, Multi-national Study to Evaluate the Safety and Tolerability of Oral Bay 63-2521 (1 Mg, 1.5 Mg, 2 Mg, or 2.5 Mg TID) in Patients with Chronic Thromboembolic Pulmonary Hypertension (Study 11349)			20 483		
Hirsch A.	Sunnybrook Health Sciences Centre (Toron	A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer, RASTEN			7 455		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Hirsch A.	icon Clinical Research	A Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy			1 974		
Jagoe T.	Immunotec recherche	Effect of Imn 1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung			3 500		
Kader T.	GlaxoSmithKline Inc. USA	Tide Clinical Trials Management Agreement			5 000		
Kader T.	YM BioSciences	A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification with Addition of Bolus Insulin Aspart in Subjects with Type 2 Diabetes Inadequately Controlled on Basal Insuli			4 600		
Kahn S.	Sanofi Aventis	Thrombosis Fellowship			135 000		
Kahn S.	Grouping of Canadian Comp. and Corp.	Ph+ Kahn S. - Vector Meeting			95 000		
Kahn S.	Boehringer-Ingelheim Canada Ltd.	Re-cover II - Efficacy and Safety of Dabigatran 150 Mg Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (Phase III)			71 828		
Kahn S.	Boehringer-Ingelheim Canada Ltd.	Dabigatran "Re-medy" - A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active			58 578		
Kahn S.	Sanofi Aventis	Recovery - Registry on Canadian Outpatients VTE Treatment (Recovery) - National, Prospective, Observational Cohort Study of VTE Management with the Low Molecular Weight Heparin, Enoxaprin, in the Outpatient Setting in Canada			20 000		
Kahn S.	Institut de recherche en santé d'Ottawa	"REVERSE" (Recurrent Venous Thromboembolism Risk Stratification Evaluation). A Study to Develop a CI			8 290		
Kahn S.	Institut de recherche en santé d'Ottawa	Reverse -Recurrent Venous Thromboembolism Risk Stratification Evaluation II: Validation of the "Men and Herdoo2" -A Clinical Decision Rule to Identify Patients with "Unprovoked" Venous Thromboembolism Who Can Discontinue Anticoagulants after Six Month			2 300		
Karaplis A.	Merck Frosst Canada and Company	To Assist in the Development of Educational Programs on Osteoporosis by the Multidisciplinary Osteoporosis Program of the Sir Mortimer B. Davis-Jewish General Hospital, a McGill University Teaching Hospital ("Osteoporosis Program").			2 000		
Langleben D.	Northern Therapeutics Inc.	The PHACeT Trial, Pulmonary Hypertension Assessment of Cell Therapy			21 881		
Langleben D.	Novartis Pharma Canada Inc.	A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an Add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertensio			18 642		
Langleben D.	Pfizer Canada Inc.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Investigating the Dose-response of PF00489791 on Acute Hemodynamics in Subjects with Idiopathic and Familial Pulmonary Arterial Hypertension			8 099		
Laporta D.	Hospira (USA)	A Phase Iv Open-labeled, Multi-center Study Evaluating the Hemodynamic Effects of Precedex			1 987		
Miller M.	Covance Canada Inc	Prospective Observational Study of Nosocomial Clostridium Difficile Toxin Antibody Concentrations, Incidence, and Recurrence.			241 440		
Miller M.	PPD Development LLC	E5564-G000-301 - Access: a Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Sever			65 938		
Miller M.	Cubist Pharmaceuticals Inc.	A Randomized, Double-blinded, Active-controlled, Dose Ranging Study of CB-183,315 in Patients with Clostridium Difficile Infection (CDI)			33 496		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Miller M.	Glaxosmithkline Inc. Canada	HPV008 (580299/008) - A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of Glaxosmithkline Biologicals' HPV-16/18 VLP/AS04 Vaccine Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia,			20 028		
Miller M.	Biocryst Pharmaceuticals	A Phase 3, Open-label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intra			7 035		
Miller M.	Actelion Pharmaceuticals Canada Inc.	A Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of a 10-day Twice Daily Oral Administration of 3 Doses of ACT-179811 in Subjects with Clostridium Difficile Infection (CDI)			4 610		
Miller M.	Health & Welfare Canada	Vancomycin-resistant Enterococci (VRE) Occurrence Report Protocol Canadian Nonsocomial Infection Surveillance Program (CNISP)			905		
Miller W.	Pfizer Canada Inc.	A Phase 1 Dose Escalation Trial of CP-675,206 in Combination with Gemcitabine in Patients with Chemotherapy-naive Metastatic Pancreatic Cancer			20 350		
Miller W.		FRSQ-Miller W FRSQ-CRU			17 210		
Palayew M.	Boehringer Ingelheim Canada Ltd.	A Randomised, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 ug and 5ug Tiotropium Inhalation Solution Delivered by the Respimat Inhaler with Tiotropium Inhalation Capsule			24 193		
Panasci L.	Novartis Pharma Canada Inc.	Nilotinib in Chronic Lymphocytic Leukemia (CLL)			52 480		
Panasci L.	McGill University	Evaluation of DNA-PK Inhibitors in Malignant Human Cells. (Luitpold Pharmaceutical Inc.)			37 536		
Pollak M.	Novo Nordisk A/S (Danemark)	Murine Models to Study the Effects of Diabetes and Diabetes Treatments, Including Insulin Analogues, on Cancer Behaviour			200 000		
Pollak M.	National Institutes of Health (USA) NIH	Measure Serum Leptin in PLCO/ATBC Studies			23 168		
Pollak M.	BioReliance Corporation	Bioreliance Subcontract No. BRC-55502-30			21 761		
Pollak M.	National Institutes of Health (USA) NIH	Analysis of Leptin and Adiponectin for 270 Stored Serum Samples			18 252		
Pollak M.	National Institutes of Health (USA) NIH	Fred Hutchinson - Mechanism of Energy Balance and Cancer Prevention			7 723		
Pollak M.	Oncogenex Technologies	CUOG - Canadian Urological Oncology Group - A Pilote Study Evaluating the Safety and Feasibility O			2 000		
Rudski, L.	Aventis Behring Canada	Elcami Clinic			23 000		
Schweitzer M.	Merck Frosst Canada and Company	Niemann-pick C1-like 1 (NPC111) Structure Functions Analysis in Family of Disparate Ezetimbe Responders			49 075		
Sheppard, R.	Janssen-Ortho Inc.	ASCEND-HF- Double-blind, Placebo-controlled, Multicentre Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure			39 125		
Sheppard, R.	New England Research Institute (NERI)	Topcat - Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist			13 403		
Sheppard, R.	Novartis Pharma Canada Inc.	CSPP100a2368 - A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early after Ho			10 204		
Small D.	Astra Zeneca Inc.	Asthma / Airways Centre Educational Grant			25 000		
Small D.	Pharmaceutical Product Development, PPD	A Randomized, Multi-center, Open-label Phase 3 Study of Pemetrexed-cisplatin Chemotherapy plus IMC-11F8 Versus Pemetrexed-cisplatin Chemotherapy Alone in the First-line Treatment of Patients with Nonsquamous Stage IIIb or IV Non-small Cell Lung Cancer (Ns			22 599		
Small D.	Bristol Myers Inc. Canada	Ph* Small, D - Bristol Myers-protocol CA 187017			18 984		

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Small D.	Pharmaceutical Product Development, PPD	A Randomized, Multi-center, Open-label Phase 3 Study of Gemcitabine-cisplatin Chemotherapy plus IMC-11F8 Versus Gemcitabine-cisplatin Chemotherapy Alone in the First-line Treatment of Patients with Squamous Stage IIIb or IV Non-small Cell Lung Cancer			7 750		
Tagalakis, V.	Sanofi Aventis (Canada)	Determining the Timing of Venous Thromboembolism in the Post-operative Setting: a Population Based Cohort Study			32 453		
Trifiro M.	Sanofi Aventis	Diabetes Nurse Support Program			32 500		
Trifiro M.	Boehringer Ingelheim Canada Ltd.	A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy over 52 Weeks in Patients with Type 2 Diabetes Mellit			15 876		
Vaitekunas S.	Hoffman La Roche Ltd., Canada	A Dose Ranging, Randomized, Double-blind, Parallel-group Placebo-controlled Multi-center of RO5313534 Used as Add-on Donepezil Treatment in Patients with Mild to Moderate Symptoms of Alzheimer's Disease			114 244		
Vaitekunas S.	Hoffman La Roche Ltd., Canada	Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two-Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease			7 500		
Wainberg M.	Merck Frosst	Integrase Inhibitors MK0518 (Raltegravir; Instress TM) and MK2038 and Any Salts, Solvates and Derivatives, Analogues, Modifications or Components Thereof in Any Physical Form Including but Not Limited to Amorphous and Crystallines Solids, and All			203 970		
Wainberg M.	Pfizer Canada Inc.	Does MVC Artificially Augment Plasma HIV Viremia			32 500		
Wainberg M.	International Partnership for Microbicide	Microbicides 2008-2009			30 525		
Zaharatos J.	Dynavax Technologies Corporation	An Observer-blinded, Randomized, Parallel-group, Multi-center Study Comparing the Safety and Immunog			7 763		
Zaharatos J.	Dynavax Technologies Corporation	An Observer-blinded, Randomized Study Comparing the Safety and Immunogenicity of Heplisav to License			1 334		
Clinical Research Awards							
Agulnik J.	Department of Medicine, JGH	Utility of different non-surgical biopsies in the genetic profiling and cellular differentiation of non-small cell lung cancer (NSCLC)				12 000	
Assouline S.	Department of Medicine, JGH	Combination of imatinib and chlorambucil for the treatment of patients with relapsed chronic lymphocytic leukemia and Efficacy of ribavirin for the treatment of acuter myeloid leukemia subtypes M4 and M5				12 000	
Baron M.	Department of Medicine, JGH	Statins in scleroderma				12 000	
Blostein M.	Department of Medicine, JGH	1. TIPPS (Thrombophilia in Pregnancy Prophylaxis Study): A multicenter, multinational randomised control trial of prophylactic low molecular weight heparin (LMWH) in high risk pregnant thrombophilic women				12 000	
Blostein M.	Department of Medicine, JGH	2. A Phase 3, Active (Warfarin) Controlled, Randomized, Double-blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Atrial Fibrillation					
Blostein M.	Department of Medicine, JGH	3. A Double-blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)					
Greenaway C.	Department of Medicine, JGH	The Burden of Infectious Diseases in Immigrants and Refugees: Reviewing the Evidence				12 000	
Gyger, G.	Department of Medicine, JGH	Videocapillaroscopy in systemic sclerosis and inflammatory myopathy				8 000	

NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards	Foundation
Hilzenrat, N.	Department of Medicine, JGH	Short Term Memory Defect in Hepatitis C Patients Treated with Interferon				8 000	
Kader T.	Department of Medicine, JGH	C-peptide levels and how they predict insulin response in type two diabetic patients who have failed oral agents				12 000	
Miller M	Department of Medicine, JGH	Household transmission of C. difficile				12 000	
Nessim, S.	Department of Medicine, JGH	The Relationship Between Peritoneal Transport Status and Vitamin D Deficiency Among Peritoneal Dialysis Patients				12 000	
Rudski L.	Department of Medicine, JGH	Echocardiography-based research on the right heart				12 000	
Sakr, L.	Department of Medicine, JGH	Understanding Phenotypical Heterogeneity of Potentially Curable Non-Small Cell Lung Cancer Using Cluster Analysis				8 000	
Schweitzer M.	Department of Medicine, JGH	Atorvastatin treatment in abdominal aortic aneurysm (AAA)				12 000	
Tagalakis, V.	Department of Medicine, JGH	Epidemiology of venous thrombosis and pharmacoepidemiology				8 000	
Sheppard, R.	Department of Medicine, JGH	Dysfunction of stress response systems and adverse cardiac remodeling after myocardial infarction				8 000	
Elizov, M.	Department of Medicine, JGH	Mentorship in Clinical Medicine				8 000	
TOTALS			18 837 543	1 152 528	4 720 080	168 000	3 532 603